KROS

Keros Therapeutics (KROS)

Keros Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:KROS

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/18	06 : 17	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KROS	Keros Therapeutics Inc
2024/06/18	06 : 15	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:KROS	Keros Therapeutics Inc
2024/06/18	05 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KROS	Keros Therapeutics Inc
2024/06/18	05 : 01	GlobeNewswire Inc.	Keros Therapeutics Announces Leadership Updates	NASDAQ:KROS	Keros Therapeutics Inc
2024/06/17	19 : 07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KROS	Keros Therapeutics Inc
2024/06/17	19 : 00	GlobeNewswire Inc.	Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association	NASDAQ:KROS	Keros Therapeutics Inc
2024/06/04	21 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KROS	Keros Therapeutics Inc
2024/06/04	21 : 00	GlobeNewswire Inc.	Keros Therapeutics to Host a Corporate Update Conference Call and Webcast	NASDAQ:KROS	Keros Therapeutics Inc
2024/06/04	05 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KROS	Keros Therapeutics Inc
2024/06/04	05 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KROS	Keros Therapeutics Inc
2024/06/04	05 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KROS	Keros Therapeutics Inc
2024/06/03	21 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KROS	Keros Therapeutics Inc
2024/06/03	21 : 00	GlobeNewswire Inc.	Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference	NASDAQ:KROS	Keros Therapeutics Inc
2024/05/31	05 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KROS	Keros Therapeutics Inc
2024/05/29	05 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KROS	Keros Therapeutics Inc
2024/05/29	05 : 01	GlobeNewswire Inc.	Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors	NASDAQ:KROS	Keros Therapeutics Inc
2024/05/14	23 : 00	GlobeNewswire Inc.	Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association	NASDAQ:KROS	Keros Therapeutics Inc
2024/05/08	21 : 03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:KROS	Keros Therapeutics Inc
2024/05/08	21 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KROS	Keros Therapeutics Inc
2024/05/08	21 : 00	GlobeNewswire Inc.	Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results	NASDAQ:KROS	Keros Therapeutics Inc
2024/03/14	21 : 00	GlobeNewswire Inc.	Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes	NASDAQ:KROS	Keros Therapeutics Inc
2024/03/06	22 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KROS	Keros Therapeutics Inc
2024/03/05	22 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KROS	Keros Therapeutics Inc
2024/03/05	22 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KROS	Keros Therapeutics Inc
2024/03/05	22 : 00	GlobeNewswire Inc.	Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference	NASDAQ:KROS	Keros Therapeutics Inc
2024/02/29	06 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KROS	Keros Therapeutics Inc
2024/02/29	06 : 01	GlobeNewswire Inc.	Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:KROS	Keros Therapeutics Inc
2024/02/24	07 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KROS	Keros Therapeutics Inc
2024/02/16	10 : 41	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KROS	Keros Therapeutics Inc
2024/02/16	10 : 40	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KROS	Keros Therapeutics Inc